Michael Gendreau
Chief Medical Officer Dogwood Therapeutics
R. Michael Gendreau, M.D., Ph.D. is the Chief Medical Officer of Dogwood Therapeutics. Dr. Gendreau has been a healthcare consultant specializing in developing late stage treatments for pain and CNS disorders. He received his B.S. in chemistry from Ohio University and his M.D./Ph.D. in medicine and pharmacology from The Ohio State University College of Medicine. Before starting his own consulting firm, Dr. Gendreau worked at Cypress Bioscience, Inc. holding various positions including Vice President of Research and Development and Chief Medical Officer. Before joining Cypress Bioscience, Inc., Dr. Gendreau was Vice President of Research and Development and Chief Medical Officer for MicroProbe Corporation, a developer and manufacturer of DNA/RNA probe-based diagnostic and therapeutic products.
Seminars
- A late-stage Phase 2 development program applying tetrodotoxin-based sodium channel modulation to treat chemotherapy-induced neuropathic pain
- Achieving durable pain reduction while minimizing CNS and systemic safety liabilities associated with chronic pain therapies
- Establishing clinical proof of concept for selective ion channel modulation in nonopioid pain management
- Discussing how programs evolved in response to clinical data and operational realities
- Sharing insights gained through adaptation, iteration, and risk management during development
- Informing future discovery and development choices with experience-based perspective
